This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



caplacizumab (Cablivi®)


Reference No. 2953

Publication date:
06/03/2019


Appraisal information

caplacizumab (Cablivi®) 10 mg powder and solvent for solution for injection


Company: Sanofi
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: 2953
Ratification by Welsh Government: 05/03/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, caplacizumab (Cablivi®) cannot be endorsed for use within NHS Wales for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, in conjunction with plasma exchange and immunosuppression
Statement of Advice (SOA)
Download